JusGlobal removes such risks and accelerates innovation while increasing fundamentals such as safety, accuracy, quality control, communications and risk management. JusGlobal is delivered by a multi-industry team each performing at the top of their respective professions -- and nearly all command an unrivaled understanding of the vicissitudes of the current world business market, given their extensive international experience.
The JusGlobal Advisory Board united with Chairman O’Brien is the team that protects corporate boards of directors and individual shareholders as well as venture capitalists; and we provide full support to the executive management and product development teams of our clients. The patented JusGlobal platform introduces solutions that can rapidly generate market growth, attract increased investor interest or position a company for a profitable merger or acquisition.
The JusGlobal Apps
JusGlobal is a team of innovators who are applying their industry insights to introduce revolutionary processes to the world of business that can preserve billions in budgetary capital through optimal asset allocation.
JusGlobal enables clients to introduce their products and services in less time, disrupting competition and accelerating profit and ROI.
We’ve already achieved in delivering a groundbreaking innovation in access to law firm services for every type of client the world over; and our clinical trials guidance and technology will save the pharmaceutical, biotechnology and medical devices industries billions in development costs while advancing the speed of profit.
Our Jus-Health transforms health care delivery to ease patient burdens and inconveniences while boosting the financial balance sheet for physician and hospital groups as well as retail pharmacies. And we won’t ever rest when it comes to applying our capabilities to protect investors – we’re growing our highly credentialed team every day and delivering industry-changing insights that will alter the landscape of business at the intersection of quality, security, safety and profitability.
JusGlobal Empowers OrganizationsAs JusGlobal, we set out to challenge and resolve current faltering ways of executing business. JusGlobal empowers organizations to excel in their passions and deliver best-in-class products and services quicker and more efficiently, which leads to healthy ROI.
Protect & Reward InvestorsWether a multinational corporation seeking to further international commerce, or a small company with a niche product that would like to attract acquisition interest, JusGlobal can introduce the exact solutions to accomplish business goals, and protect and reward investors.
Introduce JusGlobal to Your Investment Enterprise
JusGlobal wants to hear from investors.We are happy to meet with Boards of Directors, attend shareholder meetings and introduce our innovations to your executive management team.
We have access to the most elite thought leaders traversing global industry -- and we can deliver such teams to any investor-centric organization by offering customized solutions that upend industry status quo while elevating brand value.
JusGlobal can transform virtually any organization with a precise solution for the business challenges that threaten corporate valuation, stock price and market position.
JusGlobal wants to hear from venture capitalists. We advise on decisions regarding investment, capital deployment and operational efficiencies. We foster promising concepts into marketplace revolutions
Contact us to begin a conversation that will optimize your ROI. JusGlobal wants to hear from venture capitalists. We advise on decisions regarding investment, capital deployment and operational efficiencies. We foster promising concepts into marketplace revolutions.Optimize your ROI
Our Jus-Investors Team
Jus-Investors is led by Founder, Chairman & CEO Beatrice O’Brien whose vision to combine highest credentialed industry-specific advisory with groundbreaking sector-specific technology has created a revolution that will forever enhance productivity, profitability and market valuation of organizations across myriad verticals.CEO O’Brien leads a veritable Wall Street of accomplished corporate strategists, international executives, management consultants, attorneys and regulatory authors who form the Jus-Investors Advisory Board. With access to unparalleled global talent, Jus-Investors can offer unprecedented industry intelligence to create powerful solutions that improve performance, catapult profits and maintain market credibility -- the pillars of sound investment.
From the High Courts of England and Australia to top Wall Street firms, Founder, Chairman and CEO Beatrice O’Brien brings more than 25 years of legal industry experience to the table. CEO O’Brien understands the complex nexus of global business and law that only an international lens can provide. CEO O’Brien was the first Fiji Indian attorney working at Wall Street law firm Cadwalader Wickersham & Taft.
Born in Suva in the Fiji Islands, CEO O’Brien was educated in Australia and became an (attorney) solicitor and barrister in the New South Wales Supreme Court. A facile legal mind has allowed her to develop a diverse depth of practice in litigation, corporate real estate, banking and tax law having worked in the UK and the US on some of the largest reorganization and restructuring cases in corporate history.
Ever the innovator, CEO O’Brien founded and leads Attorney Placements International (API), a global legal search, recruitment and consulting firm that facilitates law firm mergers and acquisitions moving entire legal practice groups to new firms and placing partners and associates with high-profile international clients. As an ardent educator, she has created revolutionary programs such as the New York Bar Review Quality Program which assists international attorneys in qualifying their unique skills and experience to practice in the US market.
Now, Beatrice O’Brien, in founding and leading JusGlobal, is introducing technology innovations backed by an assembly of diverse professionals with the highest credentialing to offer unprecedented insight, guidance and security across the legal, pharmaceutical, health care and military clinical trials space. CEO O’Brien speaks fluent Hindi.
A Harvard and Oxford graduate, Mr. Ramsbottom is a partner at global management consulting firm McKinsey & Company. He has extensive international business experience, having worked in London, Mainland China and Tokyo for over 25 years. Mr. Ramsbottom’s expertise includes strategy, corporate finance and business development for global enterprises and financial institutions, including private equity firms and sovereign wealth funds. Mr. Ramsbottom speaks fluent Mandarin.
Duane Lakings delivers a broad array of expertise in various primary areas of drug discovery and development to the JusGlobal enterprise. Dr. Lakings is experienced across nonclinical pharmacology, pharmacokinetics and toxicology as well as clinical safety, efficacy, chemistry, manufacturing and control of drug substances and proposed drug products and regulatory affairs. He assists pharmaceutical and biotechnology companies in evaluating results from their drug discovery and development programs, including document preparation, protocol design and implementation across multiple disciplines, as well as further evaluation of drug candidates to support regulatory submission.
Dr. Lakings has served as president of Texas-based Drug Safety Evaluation and was director of drug safety evaluations at Regeneron Pharmaceuticals in Tarrytown, New York as well as a senior research investigator II at BMS-PRI (Princeton, NJ). He has been a research scientist at The Upjohn Company in Michigan and he has conducted research for the National Cancer Institute and the University of Missouri-Columbia.
Dr. Lakings has extensive publishing credits. He has authored or co-authored 44 refereed papers and 150 company-specific papers, nine book chapters on drug development, 26 abstracts for oral/poster presentation, eight commissioned drug candidate evaluation reviews and a 300-page report on biological contract research organizations (CROs).
Anthony M. Bongiorno
Senior Legal Counsel & On-Boarding Executive
An experienced litigator in the media and entertainment fields, Mr. Bongiorno worked at CBS Corporation most of his legal career, most recently, as its global head of litigation. Mr. Bongiorno has a broad practice area skill set, which includes expertise in the areas of defamation and invasion of privacy, copyright litigation, non-compete matters, wiretapping issues, litigation risk assessment, employment discrimination cases, and general commercial litigation.
Dr. Eyal Ron adds value for JusGlobal Pharma clients in the pharmaceutical, biotechnology and medical device space by accelerating the timeline toward the value inflection point. Dr. Ron delivers an entrepreneurial thought process coupled with science-based evaluation to enhance the overarching enterprise value regarding product candidates, without creating a need for costly infrastructure to foster growth.
With three decades of experience in the development of drugs, biomaterials, devices and drug delivery systems, Dr. Ron has become known for combining science with sound business strategy, making him an ideally qualified expert on the JusGlobal team. He developed and implemented the scientific, regulatory and clinical strategy for several companies. Dr. Ron offers extensive depth in the total therapeutic development process including project management, clinical trials, regulatory compliance and approval, drug delivery systems, quality control and scale-up. Dr. Ron has authored more than 100 papers, book chapters and abstracts. He is also the inventor of 50 patents, principally in drug formulations, drug delivery, tissue engineering and biomaterials.
He has been a founder or principal formulator of biotech companies, bringing seven new medications to market. He has held the position of COO, CTO and CSO, director of pharmaceutical development and principal investigator at several pharmaceutical and biotech firms.
Dr. Ron received a PhD from Brandeis University and has completed post graduate study at Massachusetts Institute of Technology. He earned a BS at Tel Aviv University.
A leading New York banking attorney, Mr. Habert is senior vice president of multinational investment bank Jefferies Group LLC. Mr. Habert specializes in the documentation of derivative products and the regulatory analysis of securities, commodities and insolvency issues relating to derivative products.
Uniquely qualified to offer guidance in the securities arena, Mr. Habert advised and assisted the Securities and Exchange Commission (SEC) in drafting rules to implement various provisions of the Dodd Frank Wall Street Reform Act, including joining rules with the Commodities Futures Trading Commission (CFTC) relating to the definitions of swap and security-based swap, swap and security-based swap dealers and major swap and security-based swap participants. He also drafted SEC rules relating to business conduct standards, the new platforms for trading, clearing and reporting security-based swaps and conflicts of interest in asset-backed securities.
A noted trial attorney and litigation expert, Mr. Stiehl is a partner in Am Law 100 firm Loeb & Loeb LLP. His practice focuses on both complex consumer class defense as well as corporate espionage litigation and consulting, such as trade secrets and restrictive covenants. Mr. Stiehl was named a “Best Lawyer” in Trade Secrets Law: The Best Lawyers in America, published by Woodward White, Inc. (2019).
A renowned authority on legal writing, Dona Zimmerman has more than thirty years of experience in the legal education industry. She was co-founder and vice president of PMBR, a national preparation course for the Multistate Bar Examination.
Ms. Zimmerman sold PMBR to Kaplan, a US $1.5 billion education corporation.
Dr. Evan Siegel, Ph.D.
CHIEF REGULATORY OFFICER
Dr. Evan Siegel adds value for Jus- Pharma clients in the pharmaceutical, biotechnology and medical device space in the Regulatory Affairs and Product Development.
Dr. Siegel served as Chief Executive Officer of OXO Chemie Inc. from 1997 to 1999. Before he joined OXO Chemie, he was the Vice President, Regulatory Affairs and Bioethics for Medical Science Systems, Inc. Prior to that he was Director of Regulatory Consulting Services and Principal Regulatory Scientist for Quintiles, Inc., in Research Triangle Park, North Carolina. He has served in regulatory affairs and executive positions in the pharmaceutical (Astra, Syntex, and OXO Chemie), Genetics Testing Industries (Medical Science Systems); and trade association environments.
Dr. Siegel has also held positions as a Toxicology Reviewer at the US Food and Drug Administration and California Department of Health Services and, at the latter, was Chief of Special Services.
He attended Bucknall University where he received a Bachelor’s of Science degree in Physics; Rutgers University, where he earned a Masters of Science degree in Radiological Health/Health Physics; the Waksman Institute of Microbiology where he earned both his Masters and Doctor of Philosophy degrees in Virology and Molecular Biology, and was awarded Postdoctoral Fellowships in Medical Genetics and Genetics Counselling at the University of North Carolina at Chapel Hill.
Dr. Siegel is an Adjunct Professor at the University of Queensland and the Centre for the Study of Preclinical Drug Development, Brisbane, Australia, and a member of the California Lieutenant Governor’s Biotechnology Advisory Group to the California Council for Economic Development.
Patricia Blaine is a registered respiratory therapist, university instructor and accomplished medical writer. She has served as a consultant in clinical trial protocols for leading pharmaceutical companies such as Eisai, Daiichi Sankyo, Forest Laboratories and Schering-Plough.
Ms. Blaine has been a senior director of medical writing and a staff medical writer for Oxford Research, Corning-Besselaar and Schering-Plough. She has been director of clinical education at the University of Medicine and Dentistry of New Jersey (UMDNJ). Ms. Blaine provided medical writing for a poster presented at a psychiatric conference focusing on a Phase IV multi-site investigatory study on carmbamazepine.
Patricia Blaine earned a Master’s degree in Education with a concentration in Allied Health Education from Rutgers University and a Bachelor of Arts in Psychology and English from Seton Hill University (Pennsylvania).